https://www.selleckchem.com/pr....oducts/BMS-790052.ht
The standard treatment of ovarian cancer is surgery followed by a chemotherapeutic combination consisting of a platinum agent, such as cisplatin and a taxane-like paclitaxel. We previously observed that patients with ovarian cancer wild-type for had a poorer survival rate than did those with mutations. Thus, a better understanding of the molecular changes of epithelial ovarian cancer cells with wild-type in response to treatment with cisplatin could reveal novel mechanisms of chemoresistance. Gene expression profiling was performed o
Like
Comment
Share
